GUB-UCN2

1 paper4 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab

Animals1

Outcomes

Intramyocellular lipids

downin rats1

1 study

GUB-UCN2 decreases intramyocellular lipids in rats (-41% to -57%).
“reduced intramyocellular lipid content (-41% to -57%)”
Animalssoleus muscle12 weeks
GUB-UCN2 as Monotherapy and in Combination with Semaglutide Increases Muscle Mass, Reduces Fat Mass, and Improves Metabolic Outcomes in Aged Diet-Induced Obese Rats
ADA Scientific Sessions 2026 abstract5 Jun 2026

Latest

1 in 12 months

ADA Scientific Sessions 2026 Abstract5 Jun

GUB-UCN2 as Monotherapy and in Combination with Semaglutide Increases Muscle Mass, Reduces Fat Mass, and Improves Metabolic Outcomes in Aged Diet-Induced Obese Rats

Experiments in ratsSemaglutide

Paper

GUB-UCN2

Outcomes

Latest

GUB-UCN2 as Monotherapy and in Combination with Semaglutide Increases Muscle Mass, Reduces Fat Mass, and Improves Metabolic Outcomes in Aged Diet-Induced Obese Rats

Related